Home » Stocks » ITOS

iTeos Therapeutics, Inc. (ITOS)

Stock Price: $22.59 USD 0.28 (1.26%)
Updated May 11, 2021 4:00 PM EDT - Market closed
Market Cap 764.06M
Revenue (ttm) n/a
Net Income (ttm) -43.40M
Shares Out 35.10M
EPS (ttm) -2.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $22.59
Previous Close $22.31
Change ($) 0.28
Change (%) 1.26%
Day's Open 21.85
Day's Range 21.73 - 22.78
Day's Volume 141,795
52-Week Range 17.50 - 47.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company pioneering the discovery and development of ...

1 month ago - GlobeNewsWire

Upcoming events could send these stocks screaming higher or lower.

Other stocks mentioned: BIIB, NVAX
1 month ago - The Motley Fool

– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results –

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...

5 months ago - GlobeNewsWire

About ITOS

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ITOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is 49.75, which is an increase of 120.23% from the latest price.

Price Target
$49.75
(120.23% upside)
Analyst Consensus: Strong Buy